title: [Advances in the study of the anti-tumor activity of small molecule vascular disrupting agents].
abstract: Vascular disrupting agents (VDAs) have presented a new kind of anti-cancer drug in recent years. VDAs take advantage of the weakness of established tumor endothelial cells and their supporting structures. In contrast to anti-angiogenic therapy, which inhibits the outgrowth of new blood vessels, vascular targeting treatments selectively attack the existing tumor vasculature. Here we summarized the anti-tumor activities, mechanisms and clinical applications of small molecule VDAs.
authors.affiliation: State Key Laboratory of Oncology in South China, Guangzhou 510060, China.
authors.forename: Yu-chen
authors.initials: YC
authors.lastname: Cai
authors.forename: Yong
authors.initials: Y
authors.lastname: Zou
authors.forename: Li-jian
authors.initials: LJ
authors.lastname: Xian
mesh_terms: D020533:Angiogenesis Inhibitors / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D001632:Bibenzyls / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D011756:Diphosphates / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D042783:Endothelial Cells / Q000187:drug effects; D006801:Humans; D015394:Molecular Structure; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009389:Neovascularization, Pathologic; D009842:Oligopeptides / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D009943:Organophosphorus Compounds / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D012694:Serine / Q000031:analogs & derivatives / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D013267:Stilbenes / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D050257:Tubulin Modulators / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D044004:Xanthones / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D001632:Bibenzyls; D011756:Diphosphates; C455219:N-acetylcochinol-O-phosphate; D009842:Oligopeptides; D009943:Organophosphorus Compounds; C465018:Oxi 4503; D013267:Stilbenes; D050257:Tubulin Modulators; D044004:Xanthones; C066668:vadimezan; D012694:Serine; C040105:combretastatin; C105791:soblidotin; C400245:AC 7700